Previous 10 | Next 10 |
2023-06-12 17:53:16 ET The US Food and Drug Administration has expanded its approval of Ironwood Pharmaceuticals' ( NASDAQ: IRWD ) drug Linzess to include the treatment of functional constipation in children and teens. Linzess was already approved to treat adults with irritable ...
– LINZESS is the first and only FDA-approved prescription therapy for functional constipation in this patient population – – Approval brings a much-needed option to an estimated 6 million 6-17-year-olds in the U.S. 1 affected by this chronic, prevalent condition &...
2023-06-12 09:54:54 ET Despite having a successful drug on the market and making a major acquisition recently, share prices of Ironwood Pharmaceuticals (NASDAQ: IRWD) are down by 7% this year so far. Wall Street analysts take a gloomy view of its future, with average estimates calli...
2023-05-22 17:43:00 ET Ironwood Pharmaceuticals (NASDAQ: IRWD) is choosing to go the acquisition route to grow its business. On Monday, the company announced it has agreed to acquire clinical-stage biotech VectivBio Holding (NASDAQ: VECT) . Investors were clearly warm to tha...
2023-05-22 12:02:21 ET Shares of VectivBio Holdings (NASDAQ: VECT) were up more than 35% Monday morning after the clinical-stage biotech company received a buyout offer from Ironwood Pharmaceuticals (NASDAQ: IRWD) . VectivBio's shares are up more than 85% so far this...
2023-05-22 07:22:48 ET Ironwood Pharmaceuticals ( NASDAQ: IRWD ) fell ~15% in the pre-market Monday after the company focused on gastrointestinal (GI) products agreed to acquire the Swiss biotech VectivBio Holding AG ( NASDAQ: VECT ) for $17.00 per share in an all-cash...
- Transaction Advances Ironwood’s Vision of Becoming the Leading GI Healthcare Company - - Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure (SBS-IF); Potential to become Best-in-Class for SBS-IF - - Orphan...
2023-05-22 05:00:00 ET Summary Pharmaceuticals/biotechnology and healthcare providers still have good value scores. Healthcare equipment is the less attractive subsector. Fast facts on IHF, a healthcare providers ETF. 10 stocks cheaper than their peers in May. ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 1:30 p.m. ET at the New York Hilton Midtown. A live audio webcast of Ironwood’s fireside chat w...
– Additional data presentations further characterize the efficacy and safety profiles of linaclotide in this patient population – – Functional constipation affects an estimated 6 million 6-17 year-olds in the U.S. 1 ; there are currently no FDA-approved pres...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...